je.st
news
Tag: met
Rejected Landfill Company Met with Scorn at Dunn County, N.D. Commission Meeting
2015-06-22 00:46:00| Waste Age
Grand Forks Herald A group of angry Dunn County residents confronted representatives of a company that previously proposed an industrial landfill in the county after they appeared at a county commission meeting Wednesday asking for a second chance. read more
Tags: company
met
county
meeting
Merck and Samsung Bioepis Announce Pivotal Phase 3 Studies for Investigational Biosimilars SB4, Enbrel (Etanercept), and SB2, Remicade (Infliximab), Met Primary Endpoints
2015-06-10 14:46:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. & SEOUL, South Korea Data Presented for the First Time at the EULAR Annual Meeting Phase 1 Data for SB2, SB4 and SB5, an Investigational Biosimilar of Humira (Adalimumab), also Presented KENILWORTH, N.J. & SEOUL, South Korea--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd. today announced that pivotal Phase 3 clinical studies of SB4, an investigational biosimilar of Enbrel (etanercept), and SB2, an investigational biosimilar of Remicade (infliximab), met their primary endpoints, demonstrating equivalence to the originator medicine in patients with moderate to severe rheumatoid arthritis (RA) despite methotrexate therapy. Language: English Contact: Merck Media:Pamela Eisele, 267-305-3558Robert Consalvo, 908-236-1127orMerck Investors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879orSamsung Bioepis Media:Jamyung Cha, (82) 32-455-6137orSamsung Bioepis Investors:Sungjoon Park, (82) 32-455-6120 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: met
primary
studies
phase
TECOS, Mercks Cardiovascular Safety Trial of JANUVIA (sitagliptin), Met Primary Endpoint in Patients with Type 2 Diabetes
2015-06-08 22:30:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Findings Published in the New England Journal of Medicine and Presented at the American Diabetes Association Scientific Sessions Treatment with Sitagliptin Did Not Increase the Risk of Major Adverse Cardiovascular Events in the Primary Composite Endpoint, or Hospitalization for Heart Failure, Compared with Placebo KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the primary results of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS), a placebo-controlled study of the cardiovascular (CV) safety of Mercks DPP-4 inhibitor, JANUVIA (sitagliptin), added to usual care in more than 14,000 patients. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestors:Joe Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Media Capsule: Please Activate Javascript !function(d, s, id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?'http':'https',dt=new Date().getTime();if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+"://s3.amazonaws.com/contentcapsule.com/clients/Merck/tags/d5542d85-2f26-45dc-b64c-3ee84a4312ff_reg_frame.js?dt="+dt;fjs.parentNode.insertBefore(js,fjs);}}(document,"script","contentcapsule-embed-d5542d85-2f26-45dc-b64c-3ee84a4312ff"); Ticker Slug: Ticker: MRK Exchange: NYSE read more
Shell met by protestors in Seattle waters over Arctic drilling
2015-05-18 10:05:00| Climate Ark Climate Change & Global Warming Newsfeed
Blue and Green: Hundreds of people took to the water off Seattle near Shell`s Polar Pioneer drilling rig with kayaks and canoes to say no to recently approved plans to resume dangerous search for oil in Arctic waters. The sHell No protest saw hundreds on kayaks, canoes and paddleboards on Sunday standing next to the Shells Polar Pioneer drilling rig. Many held flags and signs calling for climate action. Last week, President Obama gave his approval for the oil giant to go ahead with Arctic drilling , provided...
Tags: met
shell
seattle
waters
Fiat Chrysler CEO says met with Tesla, Apple CEOs
2015-05-10 01:12:49| Automakers - Topix.net
Fiat Chrysler Chief Executive Sergio Marchionne said on Saturday that he had visited with Tesla Motors Inc, Apple Inc and Google Inc during a recent trip to California. Marchionne, speaking on the sidelines of the opening of a Maserati dealership near Toronto, said he had met with Apple Chief Executive Tim Cook and Tesla CEO and founder Elon Musk, among others, on the trip, during which he rode in Google's self-driving car.
Sites : [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] next »